Association of TNFAIP3 With Immune-mediated TTP
Recruiting
N/A
Interventional Study
Thrombotic Thrombocytopenic Purpura, Acquired
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 12 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 400 (estimated)
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to investigate whether genetic variation in the TNFAIP3 locus is associated with immune-mediated thrombotic thrombocytopenic purpura (iTTP), and whether such association is mediated by decreased expression of A20 (TNFAIP3). The study includes a case-control design to assess genotype-expression association and a cohort study to evaluate clinical outcomes such as disease relapse.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Patients:
Inclusion Criteria:
* Diagnosis of iTTP
* Above 12 years of age
* Caucasian, Italian origin
* Written informed consent to participate in the study
Exclusion Criteria:
* Patients who do not meet the above-listed criteria will be excluded from participation in the study.
Controls will b…
Contacts